CDAI Calculator - Crohn's Disease Activity Index
The Crohn's Disease Activity Index (CDAI) is the most widely used clinical scoring tool for quantifying disease activity in Crohn's disease. Developed by Best et al. in 1976, it combines 8 weighted variables collected over a 7-day symptom diary with laboratory and physical findings to produce a single composite score. A score below 150 represents clinical remission; 150 to 219 is mild disease; 220 to 450 is moderate disease; and above 450 is severe disease. Enter the values from your 7-day diary and clinical assessment below to calculate the CDAI score instantly.
Formula
Worked example
A patient with 21 liquid stools over 7 days, mild pain (score 1), poor well-being (score 2), 1 complication (arthritis), no antidiarrheal use, no abdominal mass, hematocrit 38% (male, ref 47%), and current weight 68 kg vs ideal 72 kg: Component 1 = 21 x 2 = 42; Component 2 = 1 x 5 = 5; Component 3 = 2 x 7 = 14; Component 4 = 1 x 20 = 20; Component 5 = 0 x 30 = 0; Component 6 = 0 x 10 = 0; Component 7 = (47 - 38) x 6 = 54; Component 8 = ((72 - 68) / 72) x 100 = 5.6. Total CDAI = 42 + 5 + 14 + 20 + 0 + 0 + 54 + 5.6 = 140.6, which is below 150 - clinical remission.
What is the CDAI and why does it matter?
The Crohn's Disease Activity Index was developed by Best et al. in 1976 as part of the National Cooperative Crohn's Disease Study (NCCDS), the first large multicenter randomized controlled trial in inflammatory bowel disease. Researchers identified 18 clinical variables, then used regression analysis to select the 8 most predictive and assign each a weighting factor that reflected its contribution to overall disease burden. The result is a single composite score that captures both the subjective experience of the patient (pain, well-being, bowel habits) and objective clinical findings (hematocrit, body weight, abdominal mass, extraintestinal complications). Because it was designed to measure response to treatment in clinical trials, the CDAI has become the regulatory gold standard for Crohn's disease drug development, and nearly every major trial since 1976 has used it as a primary or secondary endpoint. In practice it helps clinicians and patients track disease trajectory and define remission versus active disease in a reproducible way.
The 8 components and their weighting factors explained
Each CDAI component targets a different dimension of disease activity. Component 1 (x2) counts all liquid or soft stools over 7 days - stool frequency is the most visible marker of mucosal inflammation and malabsorption. Component 2 (x5) captures abdominal pain rated 0-3 daily and averaged; pain reflects mucosal injury, mesenteric involvement and gut dysmotility. Component 3 (x7) records general well-being rated 0-4 and is the highest-weighted symptom variable because systemic disease burden, fatigue and nutritional depletion all converge in this single patient-reported measure. Components 4 through 6 cover objective findings: extraintestinal complications (arthritis, uveitis, skin lesions, fistulae, fever - each scored 1 if present then multiplied by 20), antidiarrheal medication use (x30 - the use of opiates or diphenoxylate signals poor bowel control), and abdominal mass on physical examination scored 0, 2 or 5 and multiplied by 10. Components 7 (x6) and 8 (x1) are laboratory and anthropometric: hematocrit deviation from the sex-specific reference reflects chronic blood loss and iron deficiency anemia common in active Crohn's, while body weight below ideal indicates malnutrition from malabsorption or decreased intake, both markers of disease severity.
How to collect the 7-day symptom diary
Accurate CDAI scoring depends on a prospective 7-day diary filled in daily, not recalled at the clinic visit. Each day the patient records: the number of liquid or soft stools (running total fed into Component 1); abdominal pain rated 0 (none), 1 (mild), 2 (moderate), or 3 (severe); and general well-being rated 0 (well), 1 (slightly under par), 2 (poor), 3 (very poor), or 4 (terrible). The 7-day totals for stool count and daily averages for pain and well-being are entered into the CDAI formula. Antidiarrheal drug use (diphenoxylate, loperamide, codeine, or opiates taken specifically for diarrhea) is recorded as yes or no for the same 7-day period. Clinicians complete the physical examination component (abdominal mass) and the laboratory component (hematocrit from a complete blood count) at the clinic visit, along with an assessment of current body weight versus ideal body weight. Because the diary captures fluctuation over a week rather than a snapshot on one day, it is more representative of the true disease state than a cross-sectional assessment.
CDAI limitations and alternative scoring tools
The CDAI has well-recognized limitations. It relies heavily on subjective symptom reporting - pain, well-being and stool frequency can be influenced by functional bowel symptoms (such as irritable bowel syndrome) that are common in Crohn's patients even when mucosal inflammation has resolved. This means a patient can have a CDAI above 150 and be classified as "active" despite mucosal healing on endoscopy, a phenomenon called symptomatic response without endoscopic remission. For this reason, modern clinical trials and treat-to-target strategies supplement the CDAI with objective mucosal assessments (colonoscopy, MRI enterography, fecal calprotectin, or C-reactive protein). Alternative or complementary patient-reported tools include the Harvey-Bradshaw Index (HBI), which uses a single-day assessment and correlates well with the CDAI, the Patient-Reported Outcomes 2 (PRO-2, stool frequency and pain only), and the Simple Endoscopic Score for Crohn's Disease (SES-CD) for mucosal assessment. The CDAI remains the benchmark for comparison with historical trial data but is increasingly paired with biomarkers in contemporary clinical and research settings.
CDAI score interpretation
| CDAI score | Disease activity | Clinical meaning |
|---|---|---|
| < 150 | Remission | Target for treatment response; surgical remission < 150 after 1 week |
| 150-219 | Mild active disease | Low but active disease; may be managed without escalation |
| 220-450 | Moderate active disease | Clinically significant; response = decrease >= 70 points |
| > 450 | Severely active disease | Requires aggressive therapy; often hospitalization |
Standard CDAI cut-offs used in clinical trials and practice (Best WR et al., 1976).
Frequently asked questions
What CDAI score means Crohn's is in remission?
A CDAI score below 150 is the standard definition of clinical remission in Crohn's disease, as established by the National Cooperative Crohn's Disease Study (1976). A score below 150 is also used as a response criterion after surgery - patients are considered in surgical remission if the score falls below 150 within the first week after an intestinal resection. Some trials define "deep remission" as CDAI below 150 combined with endoscopic healing.
What counts as a clinical response on the CDAI?
A decrease in CDAI score of 70 or more points from baseline is the standard definition of a clinical response in randomized controlled trials. Some trials use a 100-point decrease as a more stringent response criterion. These thresholds distinguish a meaningful drug effect from natural disease fluctuation.
Why does hematocrit use different reference values for men and women?
The physiological normal range for hematocrit differs by sex. Men typically have a reference hematocrit of around 47% and women around 42%, reflecting hormonal differences and the effect of menstruation on red cell mass. The CDAI uses these reference values to calculate the deviation - a patient with hematocrit 38% contributes (47-38) x 6 = 54 points (male) versus (42-38) x 6 = 24 points (female). This sex-specific correction makes the anemia contribution more biologically accurate.
Does a high CDAI always mean severe inflammation?
Not necessarily. The CDAI captures symptoms, not mucosal healing. A patient with functional bowel symptoms (such as diarrhea from bile acid malabsorption or irritable bowel syndrome overlap) can score above 150 even when endoscopy shows healed mucosa. Conversely, patients with fibrostenotic Crohn's disease causing obstruction may have relatively low stool counts but severe disease on imaging. The CDAI is best interpreted alongside objective markers like C-reactive protein, fecal calprotectin, and endoscopy.
Can I use the CDAI for ulcerative colitis?
No. The CDAI was specifically designed for Crohn's disease and is not validated for ulcerative colitis (UC). The standard scoring tools for UC are the Mayo Score (also called the Disease Activity Index) and the Truelove and Witts criteria for acute severe colitis. Using a Crohn's tool for UC would give clinically meaningless results.
What is an ideal body weight for the CDAI weight component?
The original CDAI study used physician-estimated or table-based ideal body weight. Common methods include the Devine formula (males: 50 kg + 2.3 kg per inch over 5 feet; females: 45.5 kg + 2.3 kg per inch over 5 feet), the Hamwi method, or values from the Metropolitan Life tables. The CDAI only counts a weight deficit - if the patient is at or above ideal weight, Component 8 scores 0. Significant weight loss below ideal reflects malnutrition and contributes to a higher CDAI.
How often should the CDAI be calculated?
In clinical practice, the CDAI is typically calculated at scheduled follow-up visits (every 3-6 months for stable patients, more frequently during a flare or when adjusting therapy). In clinical trials it is measured at defined intervals - baseline, week 6 for induction, and weeks 26 and 52 for maintenance. The 7-day diary should ideally end the day before the clinic visit so results are current.
Sources
- Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70(3):439-444.
- Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122(2):512-530.